Effect of μ-opioids morphine and buprenorphine on the development of adjuvant arthritis in rats

Inflammation Research

Volumn 45, Issue 11, 1996, Pages 557-563

  Walker, J S ^a   Chandler, A K ^a   Wilson, J L ^a   Binder, W ^a   Day, R O ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Adjuvant arthritis; Buprenorphine; Morphine; Opioids

Indexed keywords

ANTIRHEUMATIC AGENT; BUPRENORPHINE; FREUND ADJUVANT; KAPPA OPIATE RECEPTOR; MORPHINE; MU OPIATE RECEPTOR; OPIATE RECEPTOR;

ADJUVANT DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG INDUCED DISEASE; EDEMA; HISTOLOGY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029955516     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02342227     Document Type: Article

References (46)

1. Sewell KL, Trentham DE. Pathogenesis of Rheumatoid arthritis. Lancet 1993;341:283-90.
2. Iadorola MJ, Douglass J, Civelly O. Differential activation of spinal cord dynorphin and enkephalin neurons during hyperalgesia evidence using cDNA hybridization. Brain Res 1988; 455:205-12.
3. Wei ET, Kiang JJ, Buchan P, Smith TW. Corticotropin-releasing factor inhibits neurogenic plasma extravasation in the rat paw. J Pharmacol Exp Ther 1986;238:873-84.
4. Stefano GB. Role of opioid neuropeptides in immunoregulation. Prog Neurobiol 1989;33:149-59.
5. Plotnikoff NP, Faith RE, Murgo AJ, et al. Enkephalins and Endorphins, Stress and Immune System. New York: Plenum Press, 1987.
6. Levine JD, Moskowitz MA, Basbaum AI. The contribution of neurogenic inflammation in experimental arthritis. J Immunol 1985;135:843s-7.
7. Stiller RU, Grubb BD, Schiable HG. Neurophysiological evidence for increased kappa opioidergic control of spinal cord neurons in rats with unilateral inflammation. Eur J Neurosci 1993;5:1520-7.
8. Walker JS, Howlett CR, Nayanar V. Anti-inflammatory effects of kappa-opioids in adjuvant arthritis. Life Sci 1995; 57:371-8.
9. Wilson JL, Nayanar V, Walker JS. The site of anti-arthritic action of the κ-opioid, U-50,488H, in adjuvant arthritis: importance of local administration. Br J Pharmacol 1996, 118, 1754-60.
10. Carmody JJ. Opiate receptors: An introduction. Anaesth Intensive Care 1987;15:27-37.
11. Borsodi A, Basbaum AI, Besson JM, editors. Towards a new pharmacotherapy of pain. What is the basis of opioid receptor subtypes and the interactions between them? Chichester: John Wiley, 1991:241-55.
12. Hollt V. Opioid peptide processing and receptor selectivity. Ann Rev Pharmacol Toxicol 1986;26:59-77.
13. Hazum E, Chang K, Cuatrecasas P. Specific nonopiate receptors for beta endorphin. Science 1979;205:1033-5.
14. Bussier JL, Alder MW, Rogers TJ, Eisenstein TK. Cytokine reversal of morphine-induced suppression of the antibody response. J Pharmac Exp Ther 1993;264:591-7.
15. Earl JR, Claxson AW, Blake DR, Morris CJ. Proinflammatory effects of morphine in the rat adjuvant arthritis model. Int J Tiss React 1994;16:163-70.
16. Russell NSW, Jamieson A, Callen, Rance MJ. Peripheral opioid effects upon neurogenic plasma extravasation and inflammation. Br J Pharmacol 1985;84:788P.
17. Liles JH, Flecknell PA. A comparison of the effects of buprenorphine, carprofen and flunixin following laparotomy in rats. J Vet Pharmacol Ther 1994;17,284-90.
18. Deeb B, Frooman R. Effect of buprenophine on lameness and immune response in rats. Contemp Top 1992;31:13.
19. Steinetz B, Giannina T, Butler M. The role of sulphydryl groups in three models of inflammatory disease. J Pharm Exp Ther 1973;185:139-49.
20. Ackerman NR, Rooks WH, Shott L, Genant H, Maloney P, West E. Effects of naproxen on connective tissue changes in the adjuvant arthritic rat. Arthr Rheum 1979;22:1365-73.
21. Brewster D, Humphrey MJ, Mcleavy MA. The systemic availability of buprenorphine by various routes of administration. J Pharm Pharmacol 1981;33:500-506.
22. Liles JH, Flecknell PA. The effects of buprenorphine, nalbuphine and butorphanol alone or following halothane anaesthesia on food and water consumption and locomotor movement in rats. Lab Anim 1992;26:180-9.
23. Chay PCW, Duffy BJ, Walker JS. Pharmacokinetic- Pharmacodynamic Relationships of Morphine in Neonates. Clin Pharmacol Ther 1992;51:334-42.
24. Zar JH, Kurtz B, editors. Biostatistical analysis. 2nd ed. Englewood Cliffs: Prentice-Hall; 1984.
25. Metzler CM, Elfring GL, McEwen AJ. A users manual for NONLIN and Associated programs. Biometrics 1974;30:562.
26. Litchfield J, Wilcoxan F. A simplified method evaluating dose-effect experiments. J Pharmacol Exp Ther 1949;96:99-113.
27. Walker JS, Kasmerski L. Diflunisal pharmacodynamics in experimental arthritis in rats. J Rheumatol 1988;15:1643-7.
28. Walsh SL, Preston KL, Bigelow GE, Stitzer ML. Acute administration of buprenorphine in humans: Partial agonist and blockade effects. J Pharmacol Exp Ther 1995;274:361-72.
29. Leander JD. Buprenorphine has potent kappa opioid receptor antagonist activity. Neuropharmacology 1987;26:1445-7.
30. Planas ME, Rodriguez L, Sanchez S, Pol O, Puig MM. Pharmacological evidence for the involvement of the endogenous opioid system in the response to local inflammation in the rat paw. Pain 1995;60:67-71.
31. Millan MJ, Colpaert FC. Opioid systems in the response to inflammatory pain. Neuroscience 1991;42:541-53.
32. Ferreira SH, Nakamura M. Prostaglandin hyperalgesia II. The peripheral analgesic activity of morphine, enkephalins and opioid antagonists. Prostaglandins 1979;18:191-200.
33. Brown SL, Tokuda S, Saland LC, et al. Plotnikoff NP, Faith RE, Murgo AJ, Good R, editors. Enkephalins and Endorphins stress and the immune system. Opioid peptides effects on leukocyte migration. New York: Plenum Press, 1986:367-86.
34. Dahlstrom B, Bolme P, Feyching H, Noack G, Paalzow L. Morphine kinetics in children. Clin Pharmacol Ther 1979; 26:354-65.
35. Ko WWW, Dai S. Plasma, cardiac tissue and brain morphine concentrations in acute and chronic morphine-treated rats. Clin Exp Pharmacol Physiol 1989;16:117-20.
36. Walker JS. NSAID: An update on their analgesic effects. Clin Exp Pharmacol Physiol 1995;22:27-31.
37. Jaffe JH, Martin WR, Goodman LS, Gilman A, editors. The pharmacological basis of therapeutics. Opioid analgesics and antagonists. New York: Macmillan, 1994:485-521.
38. degli Uberti EC, Petraglia F, Bondanelli M, Guo AL, Valentini A, Salvadori S, et al. Involvement of μ-opioid receptors in the modulation of pituitary-adrenal axis in normal and stressed rats. J Endocr Invest 1995;18:1-7.
39. Bryant HU, Holaday JW, Herz A, editors. Handbook of experimental pharmacology: Opioids II. Opioids in immunologic processes. Berlin: Springer Verlag, 1993: 361-92.
40. Buckingham JC, Cooper TA. Differences in hypothalamopituitary-adrenocortical activity in the rat after acute and prolonged treatment with morphine. Neuroendocrinology 1984;38:411-7.
41. Sternberg EM, Young WS III, Bernardini R, Calogero AE, Chrousos GP, Gold PW, et al. A central nervous system defect in biosynthesis of corticotrophin-releasing hormone is associated with susceptibility to streptococcal cell wall-induced arthritis in Lewis rats. Proc Natl Acad Sci USA 1989;86:4771.
42. Chang KJ, Cualtrecasas P. Novel opiate binding sites selective benzomorphan drugs. Proc Natl Acad Sci USA 1981;78:4141.
43. Suarez-Roca H, Maixner W. Morphine produces a multiphasic effect on the release of substance P from rat trigeminal nucleus slices by activating different opioid receptor subtypes. Brain Res 1992;579:195-203.
44. Stein C, Hassan AHS, Przewlocki R, Gramsch C, Peter K, Herz A. Opioids from immunocytes interact with receptors on sensory nerves to inhibit nociception in inflammation. Proc Natl Acad Sci USA 1990;87:5935-9.
45. Taub DD, Eisenstein TK, Geller EB, Adler MW, Rogers TJ. Immunomodulatory activity of μ and κ-selective opioid agonists. Proc Natl Acad Sci USA 1991;88:360-4.
46. Heinjnen CJ, Karelaars A, Ballieux RE. Beta endorphin: cytokine and neuropeptide. Immunol Rev 1991;119:41-63.